Literature DB >> 2563900

A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor.

M Chinkers1, D L Garbers, M S Chang, D G Lowe, H M Chin, D V Goeddel, S Schulz.   

Abstract

Atrial natriuretic peptide (ANP) is a polypeptide hormone whose effects include the induction of diuresis, natriuresis and vasorelaxation. One of the earliest events following binding of ANP to receptors on target cells is an increase in cyclic GMP concentration, indicating that this nucleotide might act as a mediator of the physiological effects of the hormone. Guanylate cyclase exists in at least two different molecular forms: a soluble haem-containing enzyme consisting of two subunits and a non-haem-containing transmembrane protein having a single subunit. It is the membrane form of guanylate cyclase that is activated following binding of ANP to target cells. We report here the isolation, sequence and expression of a complementary DNA clone encoding the membrane form of guanylate cyclase from rat brain. Transfection of this cDNA into cultured mammalian cells results in expression of guanylate cyclase activity and ANP-binding activity. The ANP receptor/guanylate cyclase represents a new class of mammalian cell-surface receptors which contain an extracellular ligand-binding domain and an intracellular guanylate cyclase catalytic domain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563900     DOI: 10.1038/338078a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  182 in total

1.  Three dimensional atomic model and experimental validation for the ATP-Regulated Module (ARM) of the atrial natriuretic factor receptor guanylate cyclase.

Authors:  T Duda; P Yadav; A Jankowska; V Venkataraman; R K Sharma
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

2.  Inhibition of atrial natriuretic peptide (ANP) C receptor expression by antisense oligodeoxynucleotides in A10 vascular smooth-muscle cells is associated with attenuation of ANP-C-receptor-mediated inhibition of adenylyl cyclase.

Authors:  A Palaparti; Y Li; M B Anand-Srivastava
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

3.  RNA: a method to specifically inhibit PCR amplification of known members of a multigene family by degenerate primers.

Authors:  P S Yuen; K M Brooks; Y Li
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

4.  Three dimensional atomic model and experimental validation for the ATP-Regulated Module (ARM) of the atrial natriuretic factor receptor guanylate cyclase.

Authors:  T Duda; P Yadav; A Jankowska; V Venkataraman; R K Sharma
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

Review 5.  Evolution of the membrane guanylate cyclase transduction system.

Authors:  Rameshwar K Sharma
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

6.  Regulation of ANP-stimulated guanylate cyclase in the presence of Mn2+ in rat lung membranes.

Authors:  T Nashida; A Imai; H Shimomura
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

7.  Glycosylation of asparagine 24 of the natriuretic peptide receptor-B is crucial for the formation of a competent ligand binding domain.

Authors:  R Fenrick; N Bouchard; N McNicoll; A De Léan
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

8.  Effects of atrionatriuretic factor on Ca2+ current and Cai-independent transient outward K+ current in human atrial cells.

Authors:  B Le Grand; E Deroubaix; J P Couétil; E Coraboeuf
Journal:  Pflugers Arch       Date:  1992-08       Impact factor: 3.657

Review 9.  Receptor guanylyl cyclases.

Authors:  S K Wong; D L Garbers
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

10.  Conservation of the kinaselike regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl cyclases.

Authors:  K J Koller; F J de Sauvage; D G Lowe; D V Goeddel
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.